Attached files

file filename
EX-99.1 - PRESS RELEASE - IMMUNOMEDICS INCf8k021517ex99i_immunomedics.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 15, 2017

 

Immunomedics, Inc.
(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   000-12104   61-1009366
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer Identification No.)

 

300 The American Road, Morris Plains, New Jersey   07950
(Address of principal executive offices)   (Zip Code)

 

(973) 605-8200
(Registrant’s telephone number, including area code

 

Not applicable
(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 

Item 8.01. Other events

 

On February 15, 2017, Immunomedics, Inc. issued a press release titled “Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

 

Description of Exhibit

99.1   Press Release of Immunomedics, Inc., dated February 15, 2017, titled “Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders”

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  IMMUNOMEDICS, INC.
   
  By:  /s/ Michael R. Garone
    Name: Michael R. Garone
Title:  Vice President, Finance and
           Chief Financial Officer

 

Date: February 15, 2017

 

Exhibit Index

 

Exhibit
Number
  Description
99.1   Press Release of Immunomedics, Inc., dated February 15, 2017, titled “Immunomedics Sends Letter to Stockholders Highlighting Value Creating Global Licensing Agreement, Underscoring Fulfillment of Promise to Stockholders”